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Abstract Glu-plasminogen exists in two major glycoforms (I 
and II). Glycoform I contains carbohydrate chains linked to Asn-
289 and Thr-346, whereas glycoform II is glycosylated only at 
Thr-346. Disparities in carbohydrate content lead to differences 
in the important functional properties of the zymogen, e.g. the 
kinetics of activation. The kinetics of the large ligand-induced 
conformational changes of each of the Glu-plasminogen glyco-
forms have been studied using stopped-flow fluorescence. The 
results are in accordance with a conformational change governed 
by positive co-operative binding at two weak lysine-binding sites. 
Additional glycosylation at Asn-289 in Glu-plasminogen I results 
in a two-fold increase in the overall dissociation constant of a 
ligand, ft-ans-4-aminomethyl-cyclohexane carboxylic acid. This 
effect stems directly from the reaction step during which the 
conformational changes occur. This implies a higher population 
of Glu-plasminogen I in the open conformation even in the 
absence of ligands, and thus accounts for a higher rate of 
activation of Glu-plasminogen I, in comparison with Glu-
plasminogen II. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The serine protease plasmin (EC 3.4.21.7) participates in a 
wide variety of physiological and pathological processes in-
cluding vascular thrombolysis, tumour cell invasion and an-
giogenesis (for reviews see [1,2]). It has been established that 
activation of plasminogen, the inactive precursor to plasmin, 
is enhanced upon binding to ligands, such as antifibrinolytic 
amino acids, and substrates of plasmin, such as fibrin and 
components of the extracellular matrix, which presumably 
interact with the lysine binding sites of plasminogen and exert 
their effects by changes in the conformation of plasminogen. 
The conformational changes of plasminogen have been exten-
sively studied over the past 30 years [3-15]. Lysine-analogous 
ligands, such as 6-aminohexanoic acid (6-AHA) and trans-A-
aminomethylcyclohexane carboxylic acid (?-AMCHA), are 
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K1-K5, kringle-domains of Glu-plasminogen; AH ligand, amino hexyl 
ligand; o^PI, 0C2-proteinase inhibitor; AH site, amino hexyl site as 
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known to induce a large-scale conformational change: from 
a 'closed' compact structure to an 'open' elongated structure 
[10,11,14,15]; the latter is likely to be similar to the structure 
of plasminogen when bound to fibrin [16]. We have recently 
shown, by kinetic [13] and structural experiments [15], that 
positive co-operative binding of at least two ligands to Glu-
plasminogen is required to induce a fully extended conforma-
tion of the molecule. 
Although the 'AH site' [17] of K5 binds both C-terminal 
lysine analogues and AH ligands with relatively low affinity 
[17-19], it appears to be the predominant binding site of plas-
minogen for both fibrin and cultured endothelial cells [20-22]. 
It is thought that ligand-induced conformational changes are 
due to initial binding via K5, which induces the actual change 
of conformation and facilitates the rapid binding of a second 
ligand to the LBS of K4 [13,15,23]. 
Two major glycoforms of plasminogen have been isolated 
from human plasma on the basis of their differing affinities for 
lysine-Sepharose [24-26]: type I possesses an AMinked oligo-
saccharide at Asn-289 and an O-glycosidally linked oligosac-
charide at Thr-346, whereas type II is glycosylated at Thr-346 
only. The presence of the oligo-saccharide structure at Asn-
289 is known to result in reduced affinities of plasminogen Kl 
for fibrin and cvPI [20,27] and of plasminogen K4 for mono-
cytoid U937 cells [28]. Furthermore, it appears to cause faster 
activation of Glu-plasminogen by streptokinase and uroki-
nase-type plasminogen activator [29]. 
These functional disparities between plasminogen glyco-
forms prompted us to investigate the kinetics of the ligand-
induced conformational change processes for Glu-plasmino-
gen forms I and II using the stopped-flow fluorescence kinetic 
technique, previously demonstrated for a mixture of the two 
glycoforms [12,13]. From the present experiments it is con-
cluded that glycosylation at Asn-289 affects the overall equi-
librium, but significantly affects neither the individual binding 
constants for the two allosteric sites, nor the forward rate of 
conformational change, whereas the presence of the carbohy-
drate chain at Asn-289 inhibits the rate of the reverse rate of 
the change. Thus, the open conformation is favoured in the 
presence of this oligosaccharide. 
2. Materials and methods 
2.1. Reagents 
Lysine-Sepharose 6FF and AH-Sepharose 4B were obtained from 
Pharmacia (Uppsala, Sweden), 6-AHA from Aldrich-Chemie (Stein-
heim, Germany). /-AMCHA was kindly provided as a gift from Kabi 
(Stockholm, Sweden). All other chemicals were analytical grade from 
either Fluka (Buchs, Switzerland) or Merck (Darmstadt, Germany). 
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2.2. Proteins 
Human Lys-plasminogen and aprotinin was provided from Novo 
Nordisk (Gentofte, Denmark). Human Glu-plasminogen was pre-
pared essentially as described in [30] from outdated frozen human 
plasma. Glu-plasminogen was separated from minor amounts of par-
tially degraded plasminogen on AH-Sepharose 4B as in [31]. The Glu-
plasminogen I and II were then separated by linear 6-AHA gradient 
elution (0-5 mM) of lysine-Sepharose 6FF-adsorbed plasminogen, 
leading to two partially resolved peaks. Pools were made from the 
leading edge of peak I and the trailing edge of peak II, containing 
Glu-plasminogen I and II, respectively. To ensure that essentially no 
6-AHA ([6-AHA] < 1 pM) was present in the Glu-plasminogen prep-
arations, these were extensively dialysed against buffer (0.05 M Tris-
HC1/0.1 M NaCl/pH 7.8). The concentration of Glu-plasminogen was 
determined spectrophotometrically using an A^ value of 16.2 [32], 
The identity of the proteins were verified by ELISA and SDS-PAGE. 
It was confirmed by high performance capillary electrophoresis that 
the preparations of Glu-plasminogen I and II were not cross-conta-
minated (data not shown). Protein preparations were stored in 0.05 M 
Tris-HCl/0.1 M NaCl/pH 7.8 at -20°C. 
2.3. Stopped-ftow kinetic experiments 
Stopped-flow kinetic experiments were performed at 25°C in 0.05 M 
Tris-HCl/0.1 M NaCl/pH 7.8 using a Hi-Tech Scientific PQ/SF-53 
spectrofluorimeter equipped with a high-intensity xenon arc lamp 
and a fluorescence-enhancement device. The excitation wavelength 
was 280 nm, and the slit 5 mm. Light emitted from the reaction 
mixtures was subjected to a WG 320 (320 nm cut off) filter before 
reaching the detector. 
For each of the two Glu-plasminogen glycoforms a series of experi-
ments using a range of ligand concentrations was performed. Mixing 
of protein sample (Glu-plasminogen I or II, 1.8 |0,M, final concentra-
tions) with ligand (f-AMCHA, 0.1-50 mM, final concentrations) was 
achieved in less than 1 ms. Subsequently, the intrinsic protein fluo-
rescence was measured as a function of time (up to 50-500 ms). For 
each experiment 400 data points were recorded, and data sets from 
five or six experiments performed under identical conditions were 
averaged. 
3. Results 
3.1. Theory 
Large positive fluorescence changes were observed upon 
addition of f-AMCHA to both Glu-plasminogens I and II. 
The time courses of the fluorescence changes were well de-
scribed by a single exponential function as previously reported 
for the glycoform mixture, Eq. 1 [12,13]: 
AF([L],f) =AF([L],=o){l-eXp(-£obs([L])0} (1) 
where Ar0bs([L]) is the observed first-order rate constant, and 
AF([L],f) is the relative fluorescence change observed at ligand 
concentration, [L], and time, /. AF([L],°°) is the relative fluo-
rescence change observed at equilibrium (f->°°). Values of 
AF([L],») and A:0bs([L]) were calculated for each employed 
concentration of f-AMCHA from fitting Eq. 1 to the exper-
imental data. 
Fluorescence changes as a result of ligand binding to the 
high affinity LBS of Kl are not discussed here as this binding 
event is known to be independent and does not contribute to 
the Glu-plasminogen conformational change process [12,13]. 
3.2. Glu-plasminogen I 
Fig. 1 shows a plot of the values of AF([L],=°) for Glu-
plasminogen I with various f-AMCHA concentrations, [L]. 
At high ligand concentrations ([L]>1 mM) a 12% fluores-
cence change occurs. At low ligand concentrations ([L] < 1 
mM) the data clearly show a sigmoidal behaviour (inset i). 
Inset ii is a Hill plot of the same data; the line drawn has the 
slope with the value 2.0. Fig. 2 shows the values of the ob-
served rate constant, /:0bs([L]), plotted against the concentra-
tion of f-AMCHA, [L], while the inset of Fig. 2 shows a close-
up of the first part of the curve ([L] < 1 mM). 
3.3. Glu-plasminogen II 
Fig. 3 shows the values of AF([L],oo) obtained for Glu-plas-
minogen II plotted versus f-AMCHA concentrations. The 
maximal fluorescence change was found to be 9%. As ob-
served for glycoform I, the data at low ligand concentrations 
([L] < 1 mM) show a sigmoidal behaviour (inset i). The Hill 
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Fig. 1. Glu-plasminogen I interaction with f-AMCHA; the ligand dependence of the relative fluorescence changes obtained at equilibrium. 
Equilibrium values of the large positive change of the protein fluorescence (AF([L],t»), Eq. 1) obtained after interaction of Glu-plasminogen I 
with f-AMCHA plotted against the concentration of f-AMCHA, [L]. The curve shown is that given by the fitted expression (equation 2 of 
Scheme 1). The inset shows the corresponding Hill plot, where y is the fractional saturation, AF([L],°o)/AFmax([L],°o). The resulting parameters, 
AF([L],oo) and the Hill slope, are given in Table 1. The experimental errors are within the size of the symbols. 
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Fig. 2. Glu-plasminogen I interaction with r-AMCHA; the ligand dependence of the observed rate constant. The observed value of the rate 
constant, /c0bs([L]), obtained for Glu-plasminogen I plotted against r-AMCHA concentration, [L]. The curve drawn is obtained from fitting 
equation 3 (Scheme 1) to the experimental data. The resulting parameters (Ka, Ky, k{ and fcr) from this fit are listed in Table 1. The inset 
shows a close-up of the curve for [L] s i mM. Experimental errors are within the size of the symbols. 
plot of these data also exhibits a slope of value 2.0 (inset ii). 
The variation in the Glu-plasminogen II values of the ob-
served rate constant, /c0bS([L]), is shown in Fig. 4, which also 
contains an inset with data obtained at low ligand concentra-
tions ([L] < 1 mM). 
3.4. Calculation of the kinetic parameters 
The ligand concentration dependences of the fluorescence 
data for both Glu-plasminogen I and II exhibit similar char-
acteristics to the data for the glycoform mixture [13]: the 
AF([L],°°) data show a sigmoidal behaviour for both glyco-
forms (inset i, Figs. 1 and 3) and the slopes of the Hill plot are 
2.0 (insets ii, Figs. 1 and 3). Furthermore, the profiles of the 
values of the observed rate constant, &0bS([L]), exhibit minima 
at low ligand concentrations and they approach saturating 
(maximum) values at high ligand concentrations (Figs. 2 
and 4). These characteristics suggest that the reaction scheme 
previously proposed for the Glu-plasminogen glycoform mix-
ture (Scheme 1 [13]) also is valid for each of the glycoforms 
individually. All other schemes previously considered [12,13] 
cannot account for these data. Consequently, equation 2 of 
Scheme 1 was fitted to the experimental values of fc0bs([L]) for 
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Fig. 3. Glu-plasminogen II interaction with r-AMCHA; the ligand dependence of the fluorescence changes obtained at equilibrium. Equilibrium 
values of the large positive change of the protein fluorescence (AF([L],°°), Eq. 1 obtained after interaction of Glu-plasminogen II with (-AM-
CHA plotted against the concentration of r-AMCHA, [L]. The curve shown is that given by the fitted expression (equation 2 of Scheme 1). 
The inset shows the corresponding Hill plot, where y is the fractional saturation, AF([L],oo)/AFmax([L],oo). The resulting parameters, AF([L],°°) 
and the Hill slope, are given in Table 1. The experimental errors are within the size of the symbols. 
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Fig. 4. Glu-plasminogen II interaction with i-AMCHA; the ligand dependence of the rate constant. The observed value of the rate constant, 
fc0bs([L]), obtained for Glu-plasminogen II plotted against /-AMCHA concentration, [L]. The curve drawn is obtained from fitting equation 3 
(Scheme 1) to the experimental data. The resulting parameters {Ka, Kj, k[ and kr) from this fit are listed in Table 1. The inset shows a close-
up of the curve for [L] s 1 mM. Experimental errors are within the size of the symbols. 
both glycoforms. The values of the dissociation and rate con-
stants obtained from these fits are presented in Table 1. Sim-
ilarly, the results on the maximal fluorescence changes, 
AF([L],°°)max, for the two glycoforms, listed in Table 1, were 
obtained from fitting equation 3 to the values of AF([L],<»). 
4. Discussion 
Conformational changes of Glu-plasminogen, mediated by 
binding of ligands to its weak LBSs, enhance the rate of its 
conversion into plasmin [6,32-38]. It has also been shown that 
the degree of glycosylation of the plasminogen molecule mod-
ulates its functional properties. Not only do the two Glu-
plasminogen glycoforms differ with respect to affinity to ly-
sine-Sepharose and fibrin, but they also display differences in 
kinetics of activation catalyzed by urokinase and streptoki-
nase [15,24,27,29]. A plausible explanation for these dispar-
ities is that the presence of the oligosaccharide at Asn-289 in 
Glu-plasminogen type I affects the rate of the conformational 
changes. 
In order to investigate this hypothesis the kinetics of the 
ligand-induced conformational changes were characterised for 
each of the two Glu-plasminogen glycoforms. As shown pre-
viously [13] the technique of stopped-flow intrinsic protein 
fluorescence spectroscopy allows the determination of dissoci-
Table 1 
Equilibrium and kinetic constants of the positive cooperative bind-
ing of t-AMCHA 
Hill slope 
AFmax([L], 
Ka (mM) 
K 
Kf, (mM) 
h (s-1) 
kr (S"1) 
K0 (overa 
«) (%) 
11) (mM) 
Glu-plasminogen I 
2.0 ± 0.1 
11.9 ± 0.1 
8.2 ± 0.6 
0.3 ± 0.2 
0.05 ± 0.04 
70 ± 2 
21 ±14 
0.34 ± 0.01 
Glu-plasminogen II 
2.0 ± 0.1 
8.8 ± 0.3 
7.7 ± 0.9 
2.0 ± 0.8 
0.04 ± 0.02 
74 ± 3 
150 ±60 
0.74 ± 0.03 
ation and rate constants for the process of ligand-induced 
conformational changes of Glu-plasminogen. The lysine ana-
logue, ?-AMCHA, was chosen as a model ligand for these 
studies due to its known ability to induce large changes in 
intrinsic fluorescence [13]. 
The maximal positive fluorescence changes at saturating t-
AMCHA concentrations, AF([L],oo); were found to be 11.9% 
for Glu-plg I and 8.8% for Glu-plg II, in agreement with 
results for mixtures of glycoforms [7,12,13]. The fluorescence 
changes occur at those ligand concentrations which are known 
to cause large-scale conformational changes within Glu-plas-
minogen [39] indicating that observed fluorescence changes 
directly reflect large-scale changes in conformation. 
For each of the glycoforms the experimental values of 
A:0bs([L]) and AF([L],oo) are well described by equations 2 
and 3, Scheme 1. This implies a positive co-operative process 
for each glycoform individually: binding of one ligand (step i) 
induces a conformational change (step ii), which facilitates the 
binding of an additional ligand (step iii). No significant var-
iations were observed between values of either Ka or Kp, val-
ues for each glycoform (Table 1). In contrast to this, a differ-
ence was found for the equilibrium constant of the actual 
conformational change (step ii). This arises, not from dissim-
ilar values of the forward rate constant ki, but from a large 
difference in values of the reverse rate constant, kx. Conse-
quently, it is concluded that the presence of the oligosacchar-
ide at Asn-289 causes a destabilization of the open conforma-
tion of ligand-bound Glu-plasminogen. 
Values of the kinetic parameters obtained for the two glyco-
forms are in agreement with those previously obtained for the 
glycoform mixture [13] except for a discrepancy between K§ 
values. The reason for this discrepancy remains unknown. 
However, we note that K§ is very sensitive to changes of kt 
in the fitting procedure used here. 
Scheme 1 describes the concerted fast process of the coop-
erative ligand induced conformational change of Glu-plasmi-
nogen with antifibrinolytic amino acids analogous to C-termi-
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kr _ [PI] 
kf [P*L] 
[L][P*L] 
A F „,„([ ' ' ] . " ) 
K K K, ft fi 
0) 
(iii) 
(2) 
N ( i * V H ) M2( i+V I L ] ) 
affinity for the ligand. Assuming a dynamic equilibrium be-
tween conformations, even in the absence of ligands, this re-
sult implies the existence of a higher population of open mol-
ecules for Glu-plg I than for Glu-plg II. This argument further 
implies that in the absence of ligand the rate of Glu-plasmi-
nogen I activation should be higher than that of glycoform II, 
which actually has been observed experimentally with either 
uPA or streptokinase as activator [29]. 
The results do show similar values of Kp, for both glyco-
forms. This suggests that the binding of the second allosteric 
ligand to Glu-plasminogen K4 is unaffected by the Asn-289 
oligosaccharide and therefore cannot solely account for 
the higher affinity of Glu-plg II for U937 cells [28]. Sim-
ilarly, the A"a-values implies that the glycoforms possess 
equivalent affinity for intact fibrin, as shown experimentally 
[27]. 
I + Kjm i + [ L ] / K / ? 
(K K K,J5 
(3) 
W 
Scheme 1. Reaction scheme for ligand-induced Glu-plasminogen 
conformational change. The model shown best explains the results 
on the reaction of Glu-plasminogen, P, with ligands, L. The model 
relates the fluorescence change to the change of the Glu-plasmino-
gen conformation and assumes a concerted reaction with three 
steps: (i) fast formation of the first complex, PL, (ii) change of the 
conformation of PL to another form, P*L, and (iii) fast formation 
of a 1:2 Glu-plasminogen-ligand complex, P*L2. The ligands both 
interact with weak lysine binding sites. The concentration dependen-
ces of experimentally determined parameters that correspond with 
this reaction scheme are given in equations 2 and 3. The parameters 
are defined in Eq. 1 in the text. Ko is the overall dissociation con-
stant; Ka is that of the first complex, PL; Kp that of complex 
P*L2, for the dissociation of one ligand; and K is the equilibrium 
constant of step ii as defined. 
nal lysine residues. As suggested previously, the finding that 
two weak LBSs are involved strongly indicate that the first 
ligand binds K5 and the second K4 [13]. Recently, it has been 
shown that Glu-plasminogen undergoes conformational 
change in more steps than those depicted in Scheme 1, and 
that an intermediate form, similar to that of Lys-plasminogen, 
which is induced in Glu-plasminogen when benzamidine binds 
the LBS of K5 [15], also exists on the reaction pathway. Ben-
zamidine is an AH ligand, and binds weakly if at all to K4. It 
is likely, therefore, that the closed to open conformational 
equilibrium cannot be shifted entirely towards the open con-
formation with benzamidine. Scheme 1 depicts the minimum 
number of necessary steps, required to explain the kinetic 
results. Any number of further steps may exist as long as 
they are significantly fast kinetically that the initial conforma-
tional change (step ii) remains the rate limiting step. Indeed 
this appears to be the case as experiments on f-AMCHA-in-
duced conformational changes of Lys-plasminogen (glycoform 
mixture) small fluorescence changes of a fast reaction were 
seen (AFmax([L],oo) ss4%) and equilibrium was achieved with-
in the dead time ( ~ 1 ms) of the apparatus (results not 
shown). These data are in accordance with the conclusions 
reached in [15]. 
The observed different kT values of the two glycoforms re-
sult in a two-fold difference in the overall dissociation con-
stant, K& (Table 1): Glu-plasminogen I displays the higher 
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